Inhibikase Therapeutics Faces Legal Dispute Amid Clinical Trials
Company Announcements

Inhibikase Therapeutics Faces Legal Dispute Amid Clinical Trials

Inhibikase Therapeutics (IKT) has provided an update.

Inhibikase Therapeutics, Inc. is confronting a legal challenge from Pivot Holding LLC, which is claiming $1.625 million plus interest over alleged breach of contract concerning milestone payments under a 2012 agreement. Despite Pivot’s demands, Inhibikase maintains that no payment is due and is prepared to aggressively defend its position while pursuing counterclaims. Amidst this dispute, the company’s forward-looking statements highlight ongoing clinical trials, regulatory efforts, and financial needs, emphasizing the inherent risks and uncertainties in their outcomes.

For a thorough assessment of IKT stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyInhibikase Therapeutics files to sell 4.76M shares of common stock for holders
TheFlyInhibikase Therapeutics files to sell 4.76M shares of common stock for holders
TheFlyInhibikase Therapeutics completes enrollment of Phase 2 ‘201’ trial
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Optimize your mobile reading experience. Download the TipRanks App today!